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Background: The COPD Assessment Test (CAT™) is a new questionnaire that has been developed recently for
measuring the COPD patient’s health status. It is known to have a good correlation with disease specific health
status measured by St. George’s Respiratory Questionnaire (SGRQ). For the wider application in clinical practice, it
has been validated in many countries. We evaluated the reliability and validity of the translated CAT questionnaire
for Thai COPD patients.
Methods: The study was designed as a cross-sectional validation study enrolling stable Thai COPD patients from
three academic centers in Thailand at a single visit. The original CAT questionnaire was translated to Thai through
linguistic validation process. The official Thai CAT and SGRQ questionnaires were filled by Thai patients after orientation
by the out-patient nurse. The reliability of all items was assessed by Cronbach’s formula for coefficient using pooled
data from all patients. The validity of the questionnaire was tested using Pearson’s correlation with SGRQ.
Results: A total of 98 Thai COPD patients completed the official Thai CAT questionnaire; 83% were male, mean age
71 years (SD 8.2), and % predicted of FEV1 56.6% (SD 20.9). The official Thai CAT questionnaire was shown to have a
high internal consistency (Cronbach's α coefficient = 0.853). The assessment of validity of official Thai CAT questionnaire
was moderately correlated with that of SGRQ (r = 0.652).
Conclusions: The official Thai CAT questionnaire has an acceptable reliability and validity. It can be expected to serve as
a short and simple tool for assessment of the health status of Thai COPD patients.
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Chronic obstructive pulmonary disease (COPD) is defined
as a preventable and treatable disease with significant
extra pulmonary effects that may contribute to the sever-
ity of the condition in many patients. COPD is a major
health concern worldwide, and it has a substantial impact
on a patient’s life. According to the treatment guidelines,
the general approach to managing COPD should address
improvement in quality of life (QoL) [1] which is defined
as an individual’s perception of his life in the context of
culture and values [2]. Many patients with COPD have
impaired health related QoL [3] and low QoL is strongly* Correspondence: chaicharn.p@cmu.ac.th
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unless otherwise stated.associated with poor prognosis of COPD [4]. Lung func-
tion tests alone does not provide a measurement of the
overall impact of COPD health status, even though they are
used for classification of disease severity [5]. Effective dia-
logue between physicians and patients during consultation
sessions can address the impact of COPD on a patient’s
QoL. St. George’s respiratory questionnaire (SGRQ), the
standard tool for assessment of QoL in COPD, is lengthy
and time consuming [6]. The COPD Assessment Test
(CAT) questionnaire developed recently in the English lan-
guage, is a short and simple, self-administered question-
naire to assess the overall impact of COPD on patients, as
well as to improve patient–physician communication [6].
It is known that the validation of the questionnaire might
be influenced by languages, cultures, and ethnicities [7,8].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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data from English speaking countries, mainly in the United
States and European countries. Our study may provide a
better understanding of the CAT in the Thai language, eth-
nicity, and cultural group. The primary objective is to
evaluate the reliability and validity of the official Thai CAT
questionnaire. The secondary objectives are to examine re-
lationships of CAT with forced expiratory volume in first
second (FEV1) and Medical Research Council (MRC) dys-
pnea score.Methods
The study was conducted as a cross-sectional validation
design with a single visit. All subjects were recruited from
chest clinics of three academic hospitals in Thailand
between April-August 2012. This study was approved
by the Research Ethics Committee, Faculty of Medicine,
Chiang Mai University; the Committee of Human Rights
Related to Research Involving Human Subjects, Faculty of
Medicine, Mahidol University; and the Ethical Review
Committee for Research in Human Subjects, Ministry of
Public Health of Thailand. Written informed consent was
obtained from each patient prior to the study. The criteria
of recruitment were patients aged over 40 years with a
diagnosis of COPD based on post-bronchodilator ratio of
FEV1/FVC < 0.7 in the past 6 months, smokers or ex-
smokers with a smoking history of more than 10 pack-
years, and no history of acute exacerbation for at least
three months prior to the enrollment. Patients with a
prior history of asthma were eligible if they were currently
diagnosed with COPD. Subjects meeting any of the fol-
lowing criteria were not enrolled in the study: current
diagnosis of asthma, current active respiratory disorders
other than COPD, e.g. lung cancer, tuberculosis or other
significant chest x-rays findings not associated with COPD
(documented within 1 year). Those who were unable to
complete questionnaires were also excluded.Study assessments and procedures
In order to assess the reliability and validity of the CAT
questionnaires, the official Thai CAT questionnaire and
St. George Respiratory Questionnaire (SGRQ) were ad-
ministered at a single clinic visit. Demographic data and
medical history were recorded. All subjects were assessed
per routine practice: post-bronchodilator FEV1, FVC, %
predicted of FEV1, and ratio of FEV1/FVC unless there
were documented results of spirometry from the past
6 months. Values were calculated using NHANES (National
Health and Nutrition Examination Survey) III refer-
ence equations [9]. However, for Asians, a correction
factor of 0.88 was applied to the FVC and FEV1 pre-
dicted [10]. Body mass index (BMI) and MRC [11]
were also assessed.Health status questionnaires
The Thai version of SGRQ and the official Thai CAT were
administered to all subjects. The SGRQ is a 50-item ques-
tionnaire designed to measure the impact of COPD on
the subject’s health-related quality of life (HRQoL). The
questionnaire was self-completed by patients over an aver-
age of 20 minutes [12]. The original CAT designed to as-
sess current health status has 8 items covering cough,
phlegm, chest tightness, breathlessness, activity limitation,
confidence, sleep, and energy. Each item is scored from 0
to 5 giving a total score ranging from 0 to 40, correspond-
ing to the best and worst health status in patients with
COPD, respectively [6]. The original CAT was translated
to the official Thai through linguistic validation process
undertaken by TransPerfect Translations, Inc. in 2009 in
accordance with the International Society for Pharmacoe-
conomics and Outcome Research translation and cultural
adaptation process for patient-reported outcomes [13].
The linguistic validation process involved both translation
of the original English CAT to Thai (forward translation)
and retranslation of the Thai CAT to English (backward
translation). The process also included a reviewer to verify
medical terms of the translation as well as a pilot test per-
formed in 5 COPD patients. The final Thai CAT version
was used for validation in this study.
Statistical analysis
Data were expressed as mean ± SD unless otherwise stated.
Comparisons of baseline characteristics between the
COPD staging groups were performed using Fisher’s
exact test for categorical variables. Continuous variables
were analyzed using a one way ANOVA or Kruskal Wallis
as appropriate. The internal consistency of the set of 8
items of Thai CAT questionnaire was estimated by apply-
ing Cronbach’s alpha coefficient and values > 0.70 were
generally considered acceptable for aggregate data [14].
The correlation between CAT with SGRQ, FEV1, and
MRC dyspnea scores were assessed using Pearson’s correl-
ation. Statistical significance was accepted at p < 0.05 and
summary results were presented as mean ± SD or N (%).
All analyses were carried out with the SPSS statistical
package, version 16 for Windows (SPSS Inc. IL, USA).
Results
Patients’ population
A total of 98 subjects from three hospitals were recruited
in this study, comprising Maharaj Nakorn Chiang Mai
Hospital (n = 40), Ramathibodi Hospital (n = 30), and
Central Chest Institute of Thailand (n = 28). The mean
age of the group was 71 years (52–89), 83% were male
with 56.6 ± 20.9 % predicted of FEV1. Results of base-
line characteristics between COPD severity stages were
comparable. We found statistically significant differ-
ences among Global initiative for Chronic Obstructive
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pnea score, lung function, and history of acute exacerba-
tions. There were no significant differences among GOLD
in terms of gender, BMI, pack-years smoking, and duration
of disease and symptoms (Table 1).
Validity
Both Thai versions of SGRQ and CAT questionnaire were
obtained from the same patients. The internal consistency
of the CAT was high with Cronbach’s alpha = 0.853.
Correlation between the CAT and the SGRQ was signifi-
cant (r = 0.652, p < 0.001) for total scores (Figure 1). Cor-
relations between the CAT and domains of SGRQ were
also significant (r = 0.576, 0.566, and 0.591, p < 0.001 for
symptoms, activity, and impact domains, respectively)
whereas the total score showed the best correlation.
The correlation between MRC dyspnea score and CAT
score was also significant (r = 0.550, p < 0.001) but not for
the % predicted of FEV1 (r = − 0.193, p = 0.109) (Table 2).
The CAT questionnaires-GOLD stage
The comparison of mean CAT score and COPD severity
stages (GOLD stages) revealed insignificantly different scores
(11.3 ± 6.7, 11.2 ± 6.9, 12.5 ± 7.3 and 16.3 ± 8.2 for GOLD I,
II, III, and IV, respectively, p = 0.142). However, patients withTable 1 Characteristics of the study population (n = 98)
I (mild) II (mo
N 14
Males 92.9
Age (years) 74.4 ± 8.8 70.8
BMI (kg/m2) 22.9 ± 3.6 21.3
Pack years 50.4 ± 46.5 38.2
Current smoker 0.0
FEV1 (% predicted) 90.2 ± 7.4 65.2
FEV1/FVC (%) 62.5 ± 4.1 56.2
SGRQ total score 37.1 ± 20.7 36.9
MRC dyspnea scale 1.8 ± 1.0 2.2
Duration of COPD (months)
By investigator report 62.5 ± 31.7 80.5
Based on post-BD ratio FEV1/FVC < 0.7 56.8 ± 32.2 42.7
Duration of chronic respiratory symptoms (months)
Cough 48.4 ± 38.7 84.3
Chronic dyspnea 54.8 ± 34.9 81.3
History of AE in the last 12 month 14.3
Number of AE in the last 12 month 0.2 ± 0.6 0.3
Family history of asthma 7.1
Data were mean ± SD or %, BMI: body mass index; FEV1 (% predicted): percentage p
expiratory volume in first second to force vital capacity; SGRQ: St George’s respiratovery severe COPD (GOLD IV) showed significantly higher
CAT scores compared to the patients with moderate COPD
(GOLD II) (p = 0.024) (Figure 2).
Discussion
The CAT was designed to measure health status of
COPD patients in clinical practice. It could be instantly
calculated and was much shorter and easier to under-
stand than the SGRQ, the standard assessment for
COPD. Indeed, patients in a previous study reported
that CAT was fairly easy, reflected well with their status,
the response options, and rank systems [6]. Our study
revealed that the official Thai CAT questionnaire had an
internal consistency with a Cronbach’s alpha of 0.853
and was comparable to that of the original version of
CAT (Cronbach’s a coefficient of 0.88) [6]. The validated
Thai version of the SGRQ was used as an instrument to
measure the validity of the official Thai CAT question-
naire. The result was significant, albeit moderate correl-
ation supporting the validity of the official Thai CAT
questionnaire (r = 0.652). This result was similar to
other findings in previous studies which varied from
moderate to high correlations with assessments using
the COPD-specific St. George's Respiratory Question-
naire (SGRQ-C) (r = 0.64 to 0.82) [6,15-17]. The CAT isCOPD GOLD stage P-value
derate) III (severe) IV (very severe)
42 28 14
78.6 82.1 85.7 0.663
± 7.3 71.3 ± 8.5 64.9 ± 7.3 0.018
± 3.7 20.6 ± 3.4 19.3 ± 3.1 0.061
± 24.6 39.8 ± 41.5 57.0 ± 29.5 0.265
14.3 0.0 0.0 0.038
± 7.7 43.1 ± 5.3 24.4 ± 3.4 <0.001
± 9.4 44.9 ± 9.4 35.6 ± 7.5 <0.001
± 19.7 35.6 ± 20.9 50.7 ± 21.1 0.123
± 0.9 2.5 ± 1.1 3.1 ± 1.2 0.015
± 75.9 76.5 ± 55.2 83.7 ± 51.3 0.788
± 36.3 49.2 ± 42.6 53.3 ± 37.3 0.600
± 97.4 76.1 ± 69.4 29.9 ± 96.7 0.584
± 96.4 74.7 ± 64.6 92.2 ± 74.6 0.644
14.3 32.1 71.4 <0.001
± 1.2 0.5 ± 0.8 2.7 ± 4.4 <0.001
14.3 21.4 7.1 0.717
redicted of forced expiratory volume in first second; FEV1/FVC: ratio of forced
ry questionnaire; MRC: Medical Research Council scale; AE: acute exacerbation.
Figure 1 Pearson correlation between scores in St George’s Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT) in 98
patients. r = 0.652, p <0.001.
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the health impairment of COPD patients. Contrary to pre-
vious reports, our study found no significant difference of
mean CAT scores across different GOLD stages (except
GOLD II and IV) [15,18] which might be due to the rea-
son that FEV1 classified by GOLD stages in this study had
poorest correlation with CAT (r = −0.193). The multiple
consequences of COPD have no relationship with airflow
limitation and as a result, FEV1 may not reflect the total
impairment caused by the disease. This was expected as
the pulmonary function measured by FEV1, on which the
GOLD classification of COPD stage is based, is not a good
predictor of health status [14]. MRC functional dyspnea is
now proven to be useful in predicting outcomes in patients
with COPD and is recommended in the routine handlingTable 2 Correlations between health status questionnaires (o
CAT SGRQ total SGRQ symptom
CAT 1 0.652** 0.576**
SGRQ
Total 0.652** 1 0.706**
Symptom 0.576** 0.706** 1
Activity 0.566** 0.882** 0.517**
Impact 0.591** 0.951** 0.600**
MRC 0.550** 0.546** 0.416**
%pred. Of FEV1 −0.193 −0.135 −0.115
**Correlations are significant at the 0.01 level. %pred. of FEV1: percent predicted of
George’s respiratory questionnaire; MRC: Medical Research Council scale.and evaluation of these patients [19]. In the present study,
we had the opportunity of testing the correlation between
CATand MRC dyspnea score. It was statistically significant
with moderate correlation (r = 0.550) which is similar to
other studies (0.50 to 0.579) [18,20,21]. Currently the most
widely used questionnaire for measuring health status in
COPD in a research setting is the SGRQ [22]. The main
disadvantages for clinical practice are its extent as it com-
prises 50 questions which are viewed by the patients as ra-
ther complicated and time consuming and because scores
can only be calculated using a computer-based system. On
the other hand, CAT could be used as an easy and reliable
tool to assess health status in COPD patients in clinical
studies and might become a useful tool in routine
clinical practice. Unlike the physician’s judgment of clinicalfficial Thai CAT and SGRQ), MRC and FEV1
SGRQ activity SGRQ impact MRC %pred. of FEV1
0.566** 0.591** 0.550** −0.193
0.882** 0.951** 0.546** −0.135
0.517** 0.600** 0.416** −0.115
1 0.725** 0.552** −0.171
0.725** 1 0.483** −0.091
0.552** 0.483** 1 −0.317**
−0.171 −0.091 −0.317** 1
forced expiratory volume in first second; CAT: COPD assessment test; SGRQ: St
Figure 2 COPD Assessment Test (CAT) scores for GOLD COPD stages. Error bars represent means ± 1 SD. Numbers above line represent
p values.
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a numerical estimate of disease impact which is reported
to be reliable across languages and countries [6,16-18].
However, it is only one part of the clinician’s toolkit, to be
used alongside spirometry, exacerbation history, and
an assessment of co-morbidity. Its role is to supplement
information obtained from lung function measurements
and assessment of exacerbation risks. Like other clinical
assessment techniques, its utility will only become fully
apparent with time. This study provides the evidence that
the official Thai CAT questionnaire is a reliable tool and is
valid for providing practicing physicians a measurement
of the impact of COPD on health status of their groups of
patients. We need further studies to demonstrate its abil-
ity to reliably measure intra-individual change, detect in-
terpretable differences to norms, and trigger or support
useful discussion between patients and physicians which
would contribute to better and more efficient care. Our
study has a limitation in that it was a cross-sectional study
based on a single visit; as a result repeatability estimated
by calculating the intraclass correlation coefficient (ICC)
was not analyzed. In addition, the validation findings were
based on three sites of academic medical centers chosen
on the basis of representing large referral centers for
COPD patients: one site from northern part and two sites
from central part of Thailand. Thus, the data might not be
reliably extrapolated to all COPD populations in Thailand.
Although the official Thai CAT questionnaire showed very
similar properties to the much more complex Thai version
of SGRQ, with a reliability of 0.853, it could not be recom-
mended to be used in making important decisions about
individuals [23]. However, it can be considered to usetogether with other clinical parameters to accurately
measure the impact of COPD on patients’ health status.
Conclusions
The official Thai CAT questionnaire is a reliable tool
and has a good validity. It can be expected to serve as a
short and simple questionnaire for assessment of the
health status of Thai COPD patients.
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